G1 Therapeutics (GTHX) PT Lowered to $74 at Needham & Company

Needham & Company analyst Chad Messer lowered the price target on G1 Therapeutics (NASDAQ: GTHX) to $74.00 (from $76.00) while maintaining a Buy rating.

Messer commented, "Following the positive myelopreservation data for trilaciclib in frontline SCLC last updated at ESMO in October, we stand on the precipice of a major expansion of randomized trilaciclib data. Before year-end we will receive an additional 107 patient data set from a similar frontline SCLC population, as well as datasets involving new chemo regimens (2nd/3rd line SCLC with topotecan) and new tumor types (1st/2nd line breast cancer with gemcitabine/carboplatin). Notably both of these studies will contain patients with prior chemo exposure which should give an indication of how well trilaciclib performs in these more fragile patients. Given the strongly positive data so far, we are buyers of GTHX into these key readouts."

You May Also Be Interested In

• Needham Starts Wealthfront Corporation (WLTH) at Buy
• Meridian Mining Plc (MNO:CN) PT Raised to GBP3.75 at BMO Capital
• Andersen Group (ANDG) PT Raised to $70 at Truist Securities